B. Riley equity purchase facility
Company: Core Scientific
The claim, verbatim
Company entered into equity purchase agreement with B. Riley Principal Capital II giving right to sell up to $100,000,000 of common stock; $20.7 million net proceeds already drawn as of October 26, 2022
Source (primary)
Core Scientific 8-K filed 2022-10-27 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗
Quote: “On July 20, 2022, the Company entered into an equity purchase agreement with B. Riley Principal Capital II, pursuant to which the Company has the right to sell to B. Riley up to $100,000,000 of shares of the Company's common stock. As of October 26, 2022, the Company has sold 13,354,892 shares of common stock under B. Riley equity line of credit for net proceeds of approximately $20.7 million.”
How we checked this
This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.
Additional evidence
confirms Core Scientific 8-K filed 2022-10-27
Quote: “On July 20, 2022, the Company entered into an equity purchase agreement with B. Riley Principal Capital II, pursuant to which the Company has the right to sell to B. Riley up to $100,000,000 of shares of the Company's common stock. As of October 26, 2022, the Company has sold 13,354,892 shares of common stock under B. Riley equity line of credit for net proceeds of approximately $20.7 million.”